Clinical trials: Solid Tumor, completed
Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
This phase I trial is studying the side effects and best dose of bevacizumab and sunitinib in treating patients with solid tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00357318
- Testing
- sunitinib malate, bevacizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors
Phase I Trial of ZIO-101 in Patients With Solid Tumors
Primary Objectives: 1. To determine the toxicities and maximum tolerated dose (MTD) of ZIO-101 when administered intravenously once a day for 5 consecutive days every 4 weeks in subjects with advanced solid tumors. 2.
- Trial name
- NCT00509782
- Testing
- ZIO-101
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Tumors, Neoplasms
Phase I Study of LB-100 With Docetaxel in Solid Tumors
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel.
- Conditions
- Tumors, Neoplasms, Cancer
- Trial name
- NCT01837667
- Testing
- LB-100 for Injection, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lixte Biotechnology Holdings, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Ro 31-7453 in Treating Patients With Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Randomized phase I trial to determine if Ro 31-7453 is more effective with or without food in…
- Trial name
- NCT00014365
- Testing
- MKC-1
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Malignancies
Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.
The purpose of this study is to determine the dose limiting toxicities, minimum tolerated dose and recommended dose for Phase II studies.
- Trial name
- NCT00162136
- Testing
- Ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- R-Pharm
Solid Tumor, Adult
Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer
Open label, single arm, dose-escalation phase I study in ambulatory patients receiving first line chemotherapy for metastatic breast cancer.
- Trial name
- NCT03600090
- Testing
- EOC202, Paclitaxel
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Solid Tumors
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
The goal of this clinical research study is to find the highest tolerable dose of valproic acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide, sorafenib, or SU011248 (sunitinib malate)…
- Trial name
- NCT00495872
- Testing
- Dasatinib, Erlotinib, Lapatinib
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasms, Colorectal Neoplasms
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies. The study is designed to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms
- Trial name
- NCT00385177
- Testing
- SN2310 Injectable Emulsion
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Achieve Life Sciences
Unspecified Adult Solid Tumor, Protocol Specific
Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors
RATIONALE: Halofuginone hydrobromide may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of halofuginone hydrobromide in treating patients who have…
- Trial name
- NCT00027677
- Testing
- halofuginone hydrobromide
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 25 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Solid Neoplasm, Stage III Pancreatic Cancer
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with…
- Conditions
- Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02897375
- Testing
- Carboplatin, Cisplatin, Palbociclib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Emory University
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006372
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Case Comprehensive Cancer Center
Sarcoma, Osteosarcoma
A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
Background GD2 is a well-characterized tumor antigen in neuroblastoma, which is also expressed on osteosarcomas and some other sarcomas.
- Conditions
- Sarcoma, Osteosarcoma, Neuroblastoma, Melanoma
- Trial name
- NCT02107963
- Testing
- Anti-GD2-CAR engineered T cells, AP1903, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Recurrent Colon Cancer, Recurrent Rectal Cancer
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of suberoylanilide hydroxamic acid when given together with fluorouracil, leucovorin, and oxaliplatin in treating patients with progressive metastatic or unresectable…
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer
- Trial name
- NCT00138177
- Testing
- oxaliplatin, leucovorin calcium, vorinostat
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Ototoxicity
Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy
Platinum based chemotherapy (mainly Cisplatin) is known to cause a variety of adverse effects, including Ototoxicity and nephrotoxicity.
- Trial name
- NCT06553157
- Testing
- Statin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Minia University
Solid Tumors
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
The primary objective of this study is: To determine the maximum tolerated dose (MTD) of sunitinib when administered once weekly or once every two weeks.
- Trial name
- NCT02058901
- Testing
- Sunitinib
- Where
- Netherlands
- Volunteers
- 101 people
- Sponsor
- Amsterdam UMC, location VUmc
Tumor
A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.
The main purpose of To evaluate the safety, tolerability and pharmacokinetic characteristics of SIBP-03（Recombinant anti-HER3 humanized monoclonal antibody injection）. A secondary purpose Assess the immunogenicity of SIBP-03.
- Trial name
- NCT05203601
- Testing
- SIBP-03
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Institute Of Biological Products
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of irinotecan followed by fluorouracil in treating patients…
- Trial name
- NCT00024141
- Testing
- fluorouracil, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumor
PBMC-based Leukocyte Immunotherapy
This is an open-label, multicenter, dose-escalation Phase Ib trial of APN401, a suspension of viable Peripheral Blood Mononuclear Cells (PBMCs) from an individual patient that have been transfected with a small interfering…
- Trial name
- PALINDROM (NCT06172894)
- Testing
- APN401
- Where
- 4 sites in Austria
- Volunteers
- 10 people
- Sponsor
- invIOs GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.